Introduction
Only 13-28% of drug-treated type 2 diabetes patients receive insulin therapy.
The late initiation of insulin reflects the general trend that it is a last
resort therapy in the treatment of type 2 diabetes. Datamonitor believes that
there will be a shift towards earlier initiation of insulin in the future, along
with increased uptake, following the introduction of non-injected insulin.
Scope of this report
- Analysis of interviews with 388 physicians in the 7 major markets,
validated via in-depth interviews with international experts
- Determination of the prevalence of type 1 and type 2 diabetes, with
forecasts to 2012
- Analysis of the use of insulin therapy in the treatment of type 2 diabetes
by line of therapy and evaluation of early vs. late initiation of insulin
- Assessment of the potential patient population for non-injected insulin:
evaluation of switch from injected insulin and add-on to OAD therapy
Research and analysis highlights
Due to rising rates of obesity and the aging population, type 2 diabetes is
an emerging epidemic: Datamonitor estimates there will be 50.1m diabetics in the
seven major markets in 2012. Despite the large patient population, Datamonitor's
physician research reveals that only 50% of type 2 diabetics across the seven
major markets are diagnosed.
The late initiation of insulin reflects the trend that insulin is a therapy
of last resort in the treatment of type 2 diabetes. Although some experts
believe that the earlier initiation of insulin is emerging, additional clinical
trials are required to support this strategy.
Non-injected insulins are expected to overcome the key unmet need in the
insulin market by providing a more convenient mode of administration, and they
are also expected to increase the overall use of insulin in type 2 diabetes
patients and shorten the time to initiation.
Key reasons to read this report
- Understand the factors limiting the use of insulin in type 2 diabetes,
based on both physician and patient perception
- Validate product forecasting based on diagnosis and treatment rates, and
the estimated future use of insulin in the treatment of type 2 diabetes
- Recognize lucrative target populations, in terms of unmet need and patient
potential, in order to successfully position developmental products
View Cart
